JEVTANA (Cabazitaxel) is a chemotherapy medication used to treat metastatic castration-resistant prostate cancer in patients who have previously received docetaxel-based chemotherapy. It works by inhibiting cancer cell growth and division.
The recommended dose of JEVTANA is 25 mg/m² administered intravenously over 1 hour every 3 weeks, in combination with prednisone. Dosing may be adjusted based on individual patient tolerance and response.
Common side effects of JEVTANA may include:
Patients should contact their healthcare provider if they experience severe side effects or any unusual symptoms.
JEVTANA is primarily used for the treatment of metastatic castration-resistant prostate cancer.
JEVTANA is administered intravenously by a healthcare professional.
If you miss a dose, contact your healthcare provider to determine the best course of action. Do not administer a double dose.
It is important to inform your healthcare provider about all medications you are taking, as some may interact with JEVTANA.